ARID1A and ARID1B mutations co-occur in patients from multiple cancer types and >30% of ARID1A-mutant cell lines harbor ARID1B-inactivating mutations [17, 18]; thus, even the combined loss of the paralogue pair is tolerated, and potentially beneficial to cancer cells. This evidence concerns the gene ARID1B and cancer.